Ironwood Pharmaceuticals has demonstrated exceptional operating leverage, with operating margins expanding from 14.7% in 2024Q1 to 70.2% in 2026Q2, driven by a 69% reduction in SG&A and stable R&D. However, this profitability is undermined by significant reven...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.31-3.1% vs $0.32 | $113M-1.6% vs $115M |
Q2 2026 May 7, 2026 | $0.24+242.9% vs $0.07 | $107M+15.6% vs $92M |
Q1 2026 Feb 25, 2026 | -$0.01-150.0% vs $0.02 | $48M-6.3% vs $51M |
Q4 2025 Nov 10, 2025 | $0.24+166.7% vs $0.09 | $122M+63.4% vs $75M |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood.
Ironwood Pharmaceuticals is a small-cap GI-focused biotech with strong LINZESS sales but looming patent expiry by 2029–2030. IRWD raised LINZESS full-year U.S. net sales guidance to $1.15–$1.2 billion and its own revenue forecast to $460–$485 million. Apraglutide, IRWD's pipeline asset for SBS-IF, showed statistically significant Phase 3 results and is key to future value.
Benchmark IRWD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Ironwood Pharmaceuticals, Inc. (IRWD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.27 | $702.9M | 28.47 | -15.72% | 8.11% | — | — | |
| $138.70 | $8.92B | -67.66 | -89.41% | 29.4% | 12.03% | — | |
| $3.48 | $859.66M | -13.38 | 22.09% | -12.35% | -36% | — | |
| $7.94 | $118.97M | -41.79 | 17.57% | -33.92% | -47.8% | — | |
| $43.39 | $2.52B | -63.81 | 8.63% | -13.23% | -10.42% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — |
Ironwood Pharmaceuticals, Inc. (IRWD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Ironwood Pharmaceuticals, Inc. (IRWD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 18, 2026·SEC
Jun 15, 2026·SEC
Get notified when IRWD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ironwood Pharmaceuticals, Inc. (IRWD) stock FAQ — growth, dividends, profitability & financials explained
Ironwood Pharmaceuticals, Inc. (IRWD) reported $389.3M in revenue for fiscal year 2025. This represents a 3621% increase from $10.5M in 2007.
Ironwood Pharmaceuticals, Inc. (IRWD) saw revenue decline by 15.7% over the past year.
Yes, Ironwood Pharmaceuticals, Inc. (IRWD) is profitable, generating $129.9M in net income for fiscal year 2025 (8.1% net margin).
Ironwood Pharmaceuticals, Inc. (IRWD) generated $185.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
